A randomized comparison of danazol and leuprolide acetate suppression of serum-soluble CD23 levels in endometriosis
article
OA: closed
CC0
⤵ 19 in-corpus citations
AI-generated summary
Danazol and leuprolide acetate significantly suppressed elevated serum-soluble CD23 levels in women with endometriosis, with levels remaining lower three months post-treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
To determine the effects of treatment with danazol and leuprolide acetate depot on serum-soluble CD23 concentrations in women with endometriosis.This randomized trial involved 20 women 18-42 years old with regular menses and known pelvic endometriosis who were recruited from a university hospital between 1993 and 1998. Ten women took 200 mg of danazol three times daily for 6 months, and the remaining ten were given 3.75 mg of leuprolide acetate depot every 28 days for 6 months. Blood-soluble CD23 levels were measured before treatment, during the last 15 days of the 6-month treatment course, and 3 months after treatment. Only one blood sample was taken from ten women without endometriosis, between the 5th and 7th days of their menstrual cycles. For statistical analysis, we used independent and paired t tests with the Pearson correlation coefficient.Soluble CD23 levels were significantly higher in women with endometriosis before treatment than in ten normal controls. Levels decreased significantly during treatment with either danazol or leuprolide acetate. Three months after treatment, soluble CD23 values remained lower than before treatment. There was no correlation between soluble CD23 concentrations and severity of endometriosis.Our findings suggest that endometriosis increases soluble CD23 levels, which can be suppressed with either danazol or leuprolide acetate injection.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (18)
- Angiogenic activity of peritoneal fluid from women with endometriosis via openalex
- Changes in immunologic variables (TNF-a, sCD8 and sCD4) during danazol treatment in patients with endometriosis. via openalex
- Deficient cellular immunity in endometriosis via openalex
- Endometriosis: Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection* via openalex
- Endometriosis: Soluble CD23 protein in the peritoneal fluid of patients with endometriosis via openalex
- Immunosuppressive effects of danazol in vitro via openalex
- Luteinized unruptured follicle in the early stages of endometriosis as a cause of unexplained infertility via openalex
- Subfertility associated with minimal to mild endometriosis. Main mechanisms. via openalex
- W1964770018 via openalex
- W1514549604 via openalex
- W2326993768 via openalex
- W2400534755 via openalex
- W2412739212 via openalex
- W2415597826 via openalex
- W2001649279 via openalex
- W2477008945 via openalex
- W2028712686 via openalex
- W2041896207 via openalex
Cited by (19)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- AVALIAÇÃO DE BIOMARCADORES EM MULHERES COM ENDOMETRIOSE E DOR USUÁRIAS DO IMPLANTE COM ETONOGESTREL OU SISTEMA INTRAUTERINO COM LEVONORGESTREL: ENSAIO CLÍNICO RANDOMIZADO 2022
- Avaliação de dois biomarcadores e de escores de dor pélvica crônica associada à endometriose em usuárias do implante com etonogestrel e do sistema intrauterino com levonorgestrel de 52 mg por 24 meses; e avaliação das vivências dos parceiros destas mulheres após o tratamento 2022
- Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months 2020
- Avaliação de biomarcadores em mulheres com endometriose e dor usuárias do implante liberador de etonogestrel ou sistema intrauterino liberador de levonorgestrel = Assessment of biomarkers among women with endometriosis-associated pain users of the etonogestrel-releasing contraceptive implant or 52-mg levonorgestrel releasing intrauterine system: randomized clinical trial 2018
- Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial 2018
- Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia 2015
- Evaluation of CA-125 and soluble CD-23 in patients with pelvic endometriosis: a case-control study 2012
- Evaluation of CA-125 and soluble CD-23 in patients with pelvic endometriosis: a case-control study 2012
- Evaluation of CA-125 and soluble CD-23 in patients with pelvic endometriosis: a case-control study 2012
- A role for Danazol in chronic lymphocytic leukemia 2012
- Avaliação do CA-125 e do CD-23 solúvel em pacientes com endometriose pélvica 2011
- Peripheral biomarkers of endometriosis: a systematic review 2010
- Avaliação do CA-125 e do CD-23 solúvel em pacientes com endometriose pélvica 2010
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- Medical Therapy for Endometriosis 2003
- Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines 2003
- Soluble ICAM-1 levels in the serum of endometriotic patients appear to be independent of medical treatment 2001
- The possible anti‐inflammatory role of circulating human leukocyte antigen levels in women with endometriosis after treatment with danazol and leuprorelin acetate depot 2001
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:13:36.046895+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK